fewer references are possible in any restricted analysis while, correspondingly, the number of articles where no bias is possible will be higher.
A manual search of journals might have identified some further articles, but I did not know which journals to look in. The 200 articles were published in 63 journals or journal supplements, as well as in a few symposia in book form. Even so, given that I made great efforts to secure as complete a sample as possible, using standard methods, I believe that any undetected articles would have been unlikely to affect the results of this study. - A decision to refer to a particular trial may well depend on the quality of the methods used, and hence I analysed only double blind trials. (Such studies are usually also randomised, thus fulfilling what are probably the two most important methodological criteria for clinical trials.) Surprisingly, many articles had no references to other double blind trials with the same drugs. Thus, the reference pattern was somewhat irrelevant, since the aim of these trials, all with ai. active control drug, was pragmatic, trying to solve the question of which drug should be preferred. 6 The trials that were least cited in the reference lists were not published in journals or books that are difficult to obtain either in the library or through a Medline search, nor did they concern unfamiliar drugs. In fact, the reference bias was caused mainly by a biased selection of references on indomethacin, the most common control drug used in the study. Reference was made only twice to trials on controls not represented in the sample. A bias in the initial classification of drugs as positive or not positive is unlikely, since it would have been impossible to foresee what given judgments would have led to in the analysis, carried out months later.
In conclusion, therefore, the reference bias shown in this study seems to be real. Such a finding has important implications, since there is no reason to believe that rheumatologists are more biased than others in selecting references. A reader tracing the literature on any new drug using the reference lists given in the articles might risk obtaining a biased sample. Reference bias has another serious implication: it may render the conclusion of the individual article less reliable. Is So long as statistical significance is used as a major criterion of acceptability for publication the published results of medical research will contain a high proportion of false positive results. Thus quantitative estimates of treatment effects taken from published work cannot be regarded as free from bias. There are established methods to calculate the power of a study, which is the probability ofdetecting a specified, important difference using a test with a set significance level. The interpretation of statistical power is satisfactory only when it is calculated with values specified at the design stage ofthe study. The proper method to assess the adequacy of the sample size is by peer review of values specified in the protocol. If this is done the significance level eventually attained is no longer relevant to selection for publication.
Importance of sample size
Manuscripts submitted to medical journals often contain serious statistical faults.' Various steps have been taken to remedy this, notably the checklists used by the BMJ,2 and there is now also in increased awareness of the need for therapeutic efficacy to be evaluated with randomised controlled trials. Nevertheless, power calculations are still rarely used. 2 Conventional significance testing ( Thus results based on studies which had a poor prospect of yielding useful information may justifiably be rejected, but only if the criterion is based on power assessed a priori.
Nature and consequences of publication bias Publication bias may be defined simply: significant results are preferred for publication. Attention was drawn to it as early as 19630 and it has been "rediscovered" several times since. Suppose the a 657 rate chosen is 0(05. Then, just 5% of studies in which Ho is valid will yield a test statistic significant at the 5% level. If attention is limited to studies that attain publication, however, the proportion of such false positive results is higher. The significance testing paradigm does not permit us to say what proportion of statistically significant results are false positives, but the effect of publication bias is to make this proportion disquietingly larger than it would otherwise be.
Correspondingly, studies selected for publication tend to contain exaggerated estimates of the main effects, and trials with truly modest treatment effects will achieve statistical significance only if random variation conveniently exaggerates these effects.9
Conversely, variation is underestimated. These biases operate more strongly the more inadequate the sample size. A study with low power, where the true treatment effect is zero or small, must grossly exaggerate it (by chance) to show significance and attain a prospect of publication. False positives and exaggerated estimates may well dominate much of medical publication. This phenomenon is likely to contribute to the disparity commonly found in the results of different studies, which leads to controversy instead of well established, consistent findings. The desire to minimise the impact of false positive assertions may result in a preference for publishing findings which refute a previous claim, rather than confirmatory results-a further source of bias.
Such external validity, but publication in a highly regarded; widely circulated journal implies such validity, however mistaken this is given the background of inadequate statistical power. Thus the researcher faces a dilemma: on the one hand, most studies he can perform will need the collaboration ofothers to attain adequate statistical power; on the other hand, any collaborative study (even ifit is feasible) will deprive him ofpersonal kudos. Only those who are remote from the researcher's dilemma-journal editors and referees, funding bodies, and (to a lesser degree) ethical committees -can uphold the highest scientific standards with no conflict ofloyalties. These agents are not obliged to accept the status quo and can refuse to support or publish inadequate research. I regard it as their prerogative, if not obligation, to do so.
A radical proposal
Selection of work for funding or publication, then, should primarily be based on reasonableness a priori: Has the design adopted (explicitly or implicitly) a good prospect of yielding useful information? "Design" here includes the study idea, scientific basis, clinical relevance, originality, and so on, as well as the study's structure and the number of subjects. If all this is satisfied then the paper should be published irrespective of whether statistical significance or the targeted size of difference was attained. The difference actually observed is irrelevant to the decision (see Mahoney,'0 p 163). The assessment of scientific validity' would therefore be the same, whether carried out before the study or after it. The only additional requirement a posteriori is adequate adherence to the protocol-in particular, attainment of the planned sample size.
The consequences of this shift in emphasis to a priori criteria are most important in the case of studies ofinadequate power. Table II contrasts what would happen to the results of these studies under the proposed rule with what is likely to happen at present. The publication of "positive" findings would be inhibited. The advantage would be the exclusion of false positives from inadequate studies, with their grossly exaggerated estimates of differences. Against this must be weighed the cost of failing to publish true positives-which would occur quite often (1-f3=05), but which are based on inadequate evidence and also overestimate the difference.
Application of this principle-to studies with adequate power would lead to more widespread publication of negative results (table III) . True negative results would be salvaged from studies of acceptable power-though these might currently be accepted anyway, especially if supplemented with confidence intervals. This (d) the sample size (specifying accrual rate and period) aimed at, with specific allowance for expected dropouts; (e) consequent statistical power and the method by which it was derived.
These parameters should be identical in the protocol and in the eventual study report. The same criterion should be used to assess validity at both stages-in particular, the write up should be assessed on the basis of the values laid down before any data were collected. The only additional requirements at the publication stage would be the completion of the study as laid down in the protocol, with full information on as many subjects as were contracted for; variability in response between subjects not grossly in excess of that planned for; and the usual standards of adequate analysis, inference, and discussion. This approach entails assessment of the parameters assumed on an a priori basis; they are to be judged in the light of knowledge current at the time the study was designed. Other results coming to light during the study should not be allowed to affect the judgment of validity (though occasionally a major advance occurring during this period may render the results no longer relevant).
Journal editors as well as grant awarding bodies could implement this proposal most effectively by requiring submission of protocols for peer review at the planning stage. In either case an independent review body could be used. Specialists in the subject could assess the reasonableness of the values supplied for the parameters on which the power calculation is based (particularly the smallest clinically important difference), and the verification of the power calculation would not be a formidable task for a statistician or other assessor familiar with this. These assessments, once performed for the protocol, would not need to be repeated for the write up. Consequently, having accepted a protocol as adequate and relevant, a journal could offer eventual publication, conditional only on completion of the study in adequate conformity to the protocol together with the usual requirements of adequate analysis, inference, and discussion. It would become normal practice to accept an article only if this had been done.
The work ofMahoney suggests that reviewers may find it difficult to comment on incomplete manuscripts. '0 Nevertheless, Mahoney's study is not an ideal model for the process I advocate, for two reasons. Firstly, his reason for the incompleteness of the manuscript was inadequate. It would be understood, however, that the material to be evaluated was only a protocol, even though it would be virtually unaltered in the eventual article-and this would become an accepted element of peer review (as it is, to a limited extent, with funding bodies). Secondly, Mahoney studied psychologists known to have entrenched, diametrically opposite beliefs, to a degree (I hope) not encountered often among doctors; knowing that results would shortly be disclosed, they would be reluctant to commit themselves unequivocally to a favourable stance, lest the results turned out to contradict their chosen position. At the stage ofreview of a protocol this possibility is more remote.
To put these recommendations into practice would be more feasible for formal, well structured study designs, such as the clinical trial, than for less formal explanatory work-for which the rationale of significance testing is more contentious. Like other alterations in editorial policy, this would best be introduced as a decisive change, as from a given date, with advance indication given, as a piecemeal approach to change is unlikely to work.' I hope that enlightened editors will take up the challenge; the lead must come from an established, prestigious journal that can afford to be choosy.
Conclusion
Publication bias is endemic and will remain so as long as the sample sizes commonly used in research are too small and the methods used to assess adequacy of sample size are deficient. Assessment by a priori criteria-in particular, systematic peer review at the planning stage-would result in a much tighter measure of control over the quality of published work, with the prospect of improvement in study design in general and statistical power in particular. Medicine and the Media AT THE ANNUAL scientific meeting of the British Paediatric fkAssociation last year the prize for the best paper presented by a young paediatrician went to a member of a research group from Oxford. Papers offered for the annual meeting are examined by the association's academic board not only for their scientific worth but also for adherence to ethical standards. This paper, later published in the Lancet,I has now been condemned by certain sections of the press and by a group ofmembers of parliament. What was the work so condemned?
Preterm infants of low birth weight live at considerable risk, particularly of cardiorespiratory failure, and the risk is increased if they have to undergo an operation. Clinical experience suggested that deep anaesthesia and narcotic analgesics would increase the risk. That and the belief that such infants have a poor perception of pain because of lack of myelinisation in the central nervous system led to the conventional practice of anaesthesia with nitrous oxide and muscle relaxants combined with artificial ventilation. In a study of40 published reports the Oxford team found that three quarters of newborn babies undergoing surgical ligation of patent ductus arteriosus had received muscle relaxants alone or with nitrous oxide.
In the preterm infant with a poor or absent ability to cry it is difficult to tell clinically whether pain and stress are being experienced, but newer biochemical methods that detect hormones and intermediary metabolites associated with stress now make the assessment of stress more possible and prompted a re-examination of the problem by the Oxford team. The team wanted to find out whether adding a little narcotic analgesic to the accepted anaesthetic regimen might prove beneficial rather than harmful. Using these metabolic methods, they therefore compared the response to surgical ligation of patent ductus arteriosus carried out under the conventional regimen with and without the narcotic analgesic fentanyl. The possibility that fentanyl might adversely affect respiration and circulation postoperatively was also studied.
A randomised trial was designed with help from the National Perinatal Epidemiology Unit in Oxford to ensure that the results were statistically valid and that a meaningful result would be recognised as soon as possible. After only eight babies in each group had been operated on the results showed that the new regimen was significantly superior to the old not only in reducing the stress response estimated biochemically but also in improving the postoperative state. Thus for the first time good scientific evidence was produced of the need to provide deeper anaesthesia during operations on these tiny infants.
This research was commended by the distinguished American paediatrician Dr William Silverman, author ofthe widely acclaimed book Human Experimentation: A Guided Step Into the Unknown.2 He wrote that the Oxford workers "deserve a loud vote ofthanks for the ethically sound effort to subject to a rigorous test opinion based on long standing practice. And their call for further study should not fall on deaf ears. It is indeed urgent to determine the pathophysiological consequences of unrelieved pain and suffering inflicted during everyday care of newborn babies."
Members of the British Paediatric Association were thus amazed and the doctors who had done the work bewildered and distressed when after a distorted report in the Daily Mail entitled, "Pain-killer shock in babies' operations" (8 July) this work became the subject of a condemnatory "press release: for immediate publication" issued by some members of parliament forming the All Party Parliamentary Pro-Life Group. The Lancet article appeared in January, the story in the Daily Mail in July, and the press release from the members of parliament in August. The press release was entitled "Inhumane baby operations slammed" and the first paragraph stated: "Fourteen members of parliament have demanded an inquiry into trials in which sixteen premature babies were given open heart surgery, eight of them without the use ofpain killers to test whether or not the babies could experience pain."
The press release then said that the General Medical Council was being asked to investigate these trials with a view to bringing those responsible before its disciplinary committee. It continued:
"In a statement Sir Bernard Braine said: 'The trials seemed to us to be even more barbarous when one considers that the babies being tested for pain were given curare, a paralysing drug, so that they would have been unable to kick or struggle even if they were in agony, the obvious intention being to keep them immobile at all costs throughout the operation. Apart from this they were given only nitrous oxide (laughing gas)."' Implying misleadingly that wisdom acquired from the research existed before it was carried out the statement went on:
"Not surprisingly post-operatively they fared far worse than the eight babies who were given pain killers. Two of the disadvantaged babies suffered from hypotension, two showed poor peripheral circulation-both of which can be indications of shock which most
